The main goal of treatment in patients with mood disorders is usually to restore a state of
psychological wellness and high functioning. Although many depressed patients do improve …

BACKGROUND: Recent studies suggest that the treatment of major depressive disorder
(MDD) with newer antidepressant drugs that simultaneously enhance norepinephrine and …

Moclobemide is a reversible inhibitor of monoamine‐oxidase‐A (RIMA) and has been
extensively evaluated in the treatment of a wide spectrum of depressive disorders and less …

The use of monoamine oxidase inhibitors (MAOIs) by psychiatrists has declined over the
past several decades with the expansion of psychiatrists' pharmacologic armamentarium …

The reversible inhibitors of monoamine oxidase type A (RIMAs) are a newer group of
antidepressants that have had much less impact on clinical psychopharmacology than …

Background Depression is common in primary care and it is associated with marked
personal, social and economic morbidity, and creates significant demands on service …

Background Depression is common in primary care and is associated with marked personal,
social and economic morbidity, thus creating significant demands on service providers. The …

Major depressive disorder is a debilitating disease that imposes significant social and
economic burdens not only on patients but also on society. Although various treatment …

This tenth anniversary review/update of fluoxetine concentrates on the past 5 years of its
clinical application. The mechanism of action of fluoxetine; its metabolism; its efficacy in …

Objectives: To determine if the classification of 'antidepressant‐induced hypomania'in DSM‐
IV is supported by available data. Methods: We reviewed the available scientific literature to …